Page 5 of 26, showing 50 records out of 1263 total, starting on record 201, ending on 250
| Publication |
Category |
Year |
|
3613. Pelletier, G., Luu-The, V., Li, S., Ren, L., Labrie, F. (2003) Morphological studies of prolactin-secreting cells in estrogen receptor alpha and estrogen receptor beta knockout mice. Neuroendocrinol, 77: 324-333. |
All publications |
2003 |
|
3612. Pelletier, G., Luu-The, V., Li, S., Ren, L., Labrie, F. (2003) Sex-related expression of 20alpha-hydroxysteroid dehydrogenase mRNA in the adult mouse. J. Histochem. Cytochem., 51 (11): 1425-1436. |
All publications |
2003 |
|
392. Roy, J., Couillard, C., Gutman, M., Labrie, F. (2003) A novel pure SERM achieves complete regression of the majority of human breast cancer tumors in nude mice. Breast Cancer Res Treat, 81: 223-229. |
All publications |
2003 |
|
32. Simard, J., Dumont, M., Labuda, D., Sinnett, D., Meloche, C., El Alfy, M., Berger, L., Lees, E., Labrie, F., Tavtigian, S.V. (2003) Prostate cancer susceptibility genes: lessons learned and challenges posed. Endocrine Related Cancer, 10: 225-259. |
All publications |
2003 |
|
3616. Sullivan, D.A., Bélanger, A., Cermak, J.M., Bérubé, R., Papas, A.S., Sullivan, R.M., Yamagami, H., Dana, M.R., Labrie, F. (2003) Are women with Sjögren's Syndrome androgen-deficient? Journal of Rheumatology, 30: 2413-2419. |
All publications |
2003 |
|
676. Tatchum-Talom, R., Martel, C., Labrie, F., Marette, A. (2003) Acute vascular effects of the selective estrogen receptor modulator EM-652 (SCH 57068) in the rat mesenteric vascular bed. J. of the European Soc. of Cardiology, 57: 535-543. |
All publications |
2003 |
|
677. Bernardi, F., Stomati, M., Luisi, S., Pieri, M., Labrie, F., Geneazzani, A.R. (2002) Effects of the new generation selective estrogen receptor modulator EM-652 and oral administration of estradiol valerate on circulating, brain, and adrenal beta-endorphin and allopregnanolone levels in intact fertile and ovariectomized rats. Fertility and Sterility, 77: 1018-1027. |
All publications |
2002 |
|
3619. Couture, J.-F., Cantin, L., Legrand, P., Luu-The, V., Labrie, F., Breton, R. (2002) Expression, crystallization and preliminary X-ray analysis of human and rabbit 20alpha-hydroxysteroid dehydrogenases in complex with NADP(H) and various steroid substrates. Acta Cryst. D. Biol. Crystallogr., D58: 135-139. |
All publications |
2002 |
|
393. Gutman, M., Couillard, S., Roy, J., Labrie, F., Candas, B., Labrie, C. (2002) Comparison of the effects of EM-652 (SCH57068), tamoxifen, toremifene, droloxifene, idoxifene, GW-5638 and raloxifene on the growth of human ZR-75-1 breast tumors in nude mice. International Journal of Cancer, 99: 273-278. |
All publications |
2002 |
|
33. Labrie, F. (2002) Androgen blockade in prostate cancer in 2002: major benefits on survival in localized disease. Mol Cell Endocrinol, 198: 77-87. |
All publications |
2002 |
|
34. Labrie, F. (2002) Endocrine-sensitive cancers of the prostate and breast, in: Baster, J., Melmed, S. et New, M., eds: Genetics in Endocrinology, Lippincott-William and Wilkins, pp 607-661. |
All publications |
2002 |
|
395. Labrie, F., Bélanger, A., Luu-The, V., Simard, J., Labrie, C. (2002) DHEA replacement therapy as a source of androgens and estrogens at menopause, in: Genazzani, A.R., Petraglia, F. et Artini, P.G., eds: Advances in Gynecological Endocrinology, Florence, Italy, Parthenon Publishing, pp 249-258. |
All publications |
2002 |
|
3625. Labrie, F., Candas, B. (2002) Letter to the Editor. Re: Does PSA reduce prostate cancer mortality?-Interpreting the Quebec Prostate Cancer Study. CMAJ, 167: 340. |
All publications |
2002 |
|
35. Labrie, F., Candas, B., Gomez, L.J., Cusan, L. (2002) Can combined androgen blockade provide long term control or possible cure of localized prostate cancer? Urology, 60: 115-119. |
All publications |
2002 |
|
396. Labrie, F., Labrie, C., Bélanger, A., Simard, J. (2002) Third and fourth generation SERMs, in: Manni, A. et Verderame, M., eds: Selective Estrogen Receptor Modulators: Research and Clinical Applications, Totowa, NJ, Humana Press Inc., pp 167-187. |
All publications |
2002 |
|
601. Leblanc, M., Labrie, C., Bélanger, A., Candas, B., Labrie, F. (2002) Pharmacokinetics of oral dehydroepiandrosterone (DHEA) in the ovariectomised cynomolgus monkey. J. Steroid Biochemistry & Molecular Biology, 81: 159-164. |
All publications |
2002 |
|
3629. Simard, J., Dumont, M., Soucy, P., Labrie, F. (2002) Perspective: Prostate Cancer Susceptibility Genes. Endocrinology, 143: 2029-2040. |
All publications |
2002 |
|
682. Simoncini, T., Varone, G., Fornari, L., Mannella, P., Labrie, F., Genazzani, A.R. (2002) Genomic and non-genomic mechanisms of nitric oxide synthesis induction in human endothelial cells by a fourth generation selective estrogen receptor modulator. J. Endocrinol, 143: 2052-2061. |
All publications |
2002 |
|
669. Barbier, O., Albert, C., Martineau, I., Vallée, M., High, K., Labrie, F., Hum, D.W., Labrie, C., Bélanger, A. (2003) Glucuronidation of the nonsteroidal antiestrogen EM-652 (SCH 57068) by human and monkey steroid conjugating UDP-glucuronosyltransferase enzymes. Mol Pharmacol, 59: 636-45. |
All publications |
2001 |
|
3632. Brawer, M.K., Crawford, E.D., Labrie, F., Mendoza-Valdz, A., Miller, P.D., Petrylak, D.P. (2001) Androgen deprivation and other treatments for advanced prostate cancer. Reviews in Urology, 3: S59-S68. |
All publications |
2001 |
|
36. Crawford, E.D., Miller, G., Labrie, F., Hirano, D., Batuello, J., Globe, M. (2001) Prostate cancer pathology, screening and epidemiology. Reviews in Urology, 3: S2-S10. |
All publications |
2001 |
|
772. Dufort, I., Labrie, F., Luu-The, V. (2001) Human types 1 and 3 3beta-hydroxysteroid dehydrogenases: differential lability and tissue distribution. J. Clin. Endocrinol. Metab., 86: 841-846. |
All publications |
2001 |
|
37. Gomella, L.G., Labrie, F., Gamito, E.J., Brawer, M.K. (2001) Prostate cancer: risk assessment and diagnostic approaches. Reviews in Urology, 3: S31-S38. |
All publications |
2001 |
|
4717. Labrie, F. (2001) Dehydroepiandrosterone (DHEA) as potential hormone replacement therapy. Références en Gynecologie Obstétrique, 8: 317-322. |
All publications |
2001 |
|
38. Labrie, F. (2001) Le cancer de la prostate: blocage combiné des androgènes comme traitement à tous les stades de la maladie. Oncologie, 3: 3-12. |
All publications |
2001 |
|
774. Labrie, F. (2001) Prostate cancer: Endocrinology of prostate cancer - intracrinology, in: Pinchera, A., Bertega, X., Binder, C., Fischer, J. et Braverman, L., eds: Endocrinology and Metabolism, pp 13-16. |
All publications |
2001 |
|
3637. Labrie, F. (2001) The Role of Androgen Therapy in Postmenopausal Women - Physiology of Androgens in Women. Supplement to Menopause Management, 11: 3-5. |
All publications |
2001 |
|
3638. Labrie, F. (2001) Unique role of hormone therapy in the management of prostate cancer at all stages of the disease, in: Syrigos, K.N., ed. Prostate cancer: biology, diagnosis and management, pp 301-314. |
All publications |
2001 |
|
399. Labrie, F., Bélanger, A., Luu-The, V., Simard, J., Labrie, C. (2001) DHEA replacement therapy as source of androgens and estrogens at menopause, in: Genazani, A.R., Petraglia, F. et Artini, P.G., eds: Advances in Gynecological Endocrinology, London, UK, Parthenon Publishing, pp 249-258. |
All publications |
2001 |
|
39. Labrie, F., Candas, B., Cusan, L., Gomez, J.L. (2001) The Laval University screening trial results (Chapter 17), in: Thompson, I.M., Resnick, M.I. et Klein, E.A., eds: Current Clinical Urology, Prostate Cancer Screening, Totowa, NJ, Humana Press Inc., pp 255-279. |
All publications |
2001 |
|
3643. Labrie, F., Candas, B., Cusan, L., Gomez, J.L., Lévesque, J., Chevrette, E., Brousseau, G. (2001) Prostate Cancer Screening: The Only Way to Early Treatment and a Major Impact on Survival. Proceeding of the VIIth International Congress of Andrology, 461-468. |
All publications |
2001 |
|
400. Labrie, F., Labrie, C., Bélanger, A., Giguère, V., Simard, J., Mérand, Y., Gauthier, S., Luu-The, V., Candas, B., Martel, C.E.A. (2001) Pure selective estrogen receptor modulators, new molecules having absolute cell specificity ranging from pure antiestrogenic to complete estrogen-like activities, in: Scolnick, E.M., ed. Advances in Protein Chemistry, San Diego, CA, Academic Press, pp 293-368. |
All publications |
2001 |
|
401. Labrie, F., Labrie, C., Bélanger, A., Simard, J., Giguère, V., Tremblay, A., Tremblay, G. (2001) EM-652 (SCH 57068), a pure SERM having complete antiestrogenic activity in the mammary gland and endometrium. J. Steroid Biochem. Mol. Biol., 79: 213-225. |
All publications |
2001 |
|
40. Labrie, F., Luu-The, V., Labrie, C., Simard, J. (2001) DHEA and its transformation into androgens and estrogens in peripheral target tissues: Intracrinology. Neuroendocrinologie, 22: 185-212. |
All publications |
2001 |
|
403. Labrie, F., Simard, A.R., Labrie, C., Bélanger, A. (2001) EM-652 (SCH57068) a pure SERM in the mammary gland and endometrium. Référence en Gynécologie Obstétrique, 8: 331-336. |
All publications |
2001 |
|
781. Luu-The, V., Dufort, I., Pelletier, G., Labrie, F. (2001) Type 5 17beta-hydroxysteroid dehydrogenase: its role in the formation of androgens in women. Mol. Cell. Endocrinol., 171: 77-82. |
All publications |
2001 |
|
3650. Nahoum, V., Gangloff, A., Legrand, P., Zhu, D.-W., Cantin, L., Zhorov, B., Luu-The, V., Labrie, F., Breton, R., Lin, S.-X. (2001) Structure of the human 3 alpha-hydroxysteroid dehydrogenase type 3 in complex with testosterone and NADP at 1.25 a resolution. J. of Biological Chemistry, 276: 41091-98. |
All publications |
2001 |
|
404. Pelletier, G., El Alfy, M., Labrie, C., Martel, C., Labrie, F. (2001) Effect of long-term treatment with the antiestrogen EM-652.HCl on pituitary estrogen receptor alpha and prolactin mRNA expression in intact, ovariectomized and GnRH-treated female rats. Neuroendocrinology, 74: 367-374. |
All publications |
2001 |
|
3652. Pelletier, G., Labrie, C., Martel, C., Li, S., Labrie, F. (2001) Role of extra-ovarian estrogens in the regulation of GnRH mRNA expression in the rat brain. J. Neuroendocrinol, 13: 678-682. |
All publications |
2001 |
|
3653. Pelletier, G., Li, S., Luu-The, V., Tremblay, Y., Bélanger, A., Labrie, F. (2001) Immunoelectron microscopic localization of three key steroidogenic enzymes (cytochrome P450scc, 3beta-hydroxysteroid dehydrogenase and cytochrome P450c17) in rat adrenal cortex and gonads. J Endocrinology, 171: 373-383. |
All publications |
2001 |
|
41. Pelletier, G., Luu-The, V., El Alfy, M., Li, S., Labrie, F. (2001) Immunoelectron microscopic localization of 3beta-hydroxysteroid dehydrogenase and type 5 17beta-hydroxysteroid dehydrogenase in the human prostate and mammary gland. J. Mol. Endocrinol., 26: 11-19. |
All publications |
2001 |
|
42. Roach III, M.J., Thrasher, J.B., Blasko, J., Raben, D., Stone, N., Katz, A., Labrie, F. (2001) Prostatectomy, brachytherapy, intensity modulated radiotherapy, hormonal-radiotherapy, salvae cryosurgery and the role of combined hormonal blokade in the treatment of prostate cancer. Reviews in Urology, 3: S49-S58. |
All publications |
2001 |
|
406. Sauvé, F., McBroom, L.D.B., Gallant, J., Moraitis, A.N., Labrie, F., Giguère, V. (2001) CIA, a novel estrogen receptor coactivator with a bifunctional nuclear receptor interacting determinant. Mol. Cell. Biol, 21: 343-353. |
All publications |
2001 |
|
3657. Singh, R., Eeles, R.A., Durocher, F., Simard, J., Edwards, S., Bodzioch, M., Teare, D., Ford, D., Dearnaley, D., Ardern-Jones, A., Labrie, F. (2001) High risk genes predisposing to prostate cancer development-do they exist? Prostate cancer and prostatic diseases, 3: 241-247. |
All publications |
2001 |
|
43. Tavtigian, S.V., Simard, J., Teng, D.H.F., Abtin, V., Baumgard, M., Beck, A., Camp, N.J., Carillo, A.R., Chen, Y., Dayananth, P., Desrochers, M., Dumont, M., Farnham, J.M., Frank, D., Frye, C., Ghaffari, S., Gupte, J.S., Hu, R., Iliev, D., Janecki, T., Kort, E.N., Laity, K.E., Leavitt, A., Leblanc, G., McArthur-Morrison, J., Pederson, A., Penn, B., Peterson, K.T., Reid, J.E., Richards, S., Schroeder, M., Smith, R., Snyder, S.C., Swedlund, B., Swensen, J., Thomas, A., Tranchant, M., Woodland, A.-M., Labrie, F., Skolnick, M.H., Neuhausen, S., Rommens, J., Cannon-Albright, L.A. (2001) A candidate prostate cancer susceptibility gene at chromosome 17p. Nat. Genet., 27: 172-180. |
All publications |
2001 |
|
3659. Zhu, D.-W., Cantin, L., Nahoum, V., Rehse, P., Luu-The, V., Labrie, F., Breton, R., Lin, S.-X. (2001) Crystallization and preliminary X-ray crystallographic analysis of the human type 3 3beta-hydroxysteroid dehydrogenase at 1.8 Å resolution. Acta Crystallogr. D., D57: 589-591. |
All publications |
2001 |
|
605. Boivin, R.P., Luu-The, V., Lachance, R., Labrie, F., Poirier, D. (2000) Structure-activity relationships of 17alpha-derivatives of estradiol as inhibitors of steroid sulfatase. J. Med. Chem., 43: 4465-4478. |
All publications |
2000 |
|
44. Candas, B., Cusan, L., Gomez, J.-L., Diamond, P., Suburu, R.E., Lévesque, J., Brousseau, G., Bélanger, A., Labrie, F. (2000) Evaluation of prostatic specific antigen and digital rectal examination as screening tests for prostate cancer. Prostate, 45: 19-35. |
All publications |
2000 |
|
407. Couillard, S., Labrie, C., Gauthier, S., Mérand, Y., Singh, S.M., Candas, B., Labrie, F. (2000) Long-term inhibitory effect of the orally active and pure antiestrogen EM-800 on the growth of human breast cancer xenografts in nude mice. Int. J. Cancer, 85: 424-429. |
All publications |
2000 |
|
45. El-Alfy, M., Pelletier, G. Hermo, L.S., Labrie, F. (2000) Unique features of the basal cells of human prostate epithelium. Microsc. Res. Tech., 51: 436-446. |
All publications |
2000 |